LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Zurück zur letzten Suche Suchhistorie
Erweiterte Suche

Ihre letzten Suchen

  1. AU="Chu, Kimberly"
  2. AU="Finton, Kathryn A K"
  3. AU="Lou Alcaine, María Luz"
  4. AU="Patterson, G Taylor"
  5. AU="Champey, Patrick R" AU="Champey, Patrick R"
  6. AU="Zyriax, Birgit-Christiane"
  7. AU="Kim, Elaine H"
  8. AU="Zhou, Gui-Xiu"
  9. AU="Baer, Rebecca J"
  10. AU="Fleck, Robert J"

Suchergebnis

Treffer 1 - 3 von insgesamt 3

Suchoptionen

  1. Artikel: Development of hairy cell leukemia in a patient after cardiac transplantation.

    Tsao, Lawrence / Chu, Kimberly E / Bhagat, Govind / Alobeid, Bachir

    Leukemia & lymphoma

    2005  Band 47, Heft 2, Seite(n) 361–363

    Abstract: Post-transplant lymphoproliferative disorders (PTLDs) are well-recognized complications of bone marrow and solid organ transplantation, comprising a heterogenous group of lymphoproliferations with a spectrum of morphologic, phenotypic and molecular ... ...

    Abstract Post-transplant lymphoproliferative disorders (PTLDs) are well-recognized complications of bone marrow and solid organ transplantation, comprising a heterogenous group of lymphoproliferations with a spectrum of morphologic, phenotypic and molecular features. Although PTLDs are usually Epstein-Barr virus-driven B-cell lymphoproliferations, T/natural killer-cell lymphoproliferations, multiple myeloma, and Hodgkin's lymphoma are also recognized as part of the PTLD spectrum. Hairy cell leukemia, a low-grade B-cell lymphoproliferation, has not been recognized as part of the PTLD spectrum. We report the first case of hairy cell leukemia occurring after cardiac transplantation. It is unclear whether this case, similar to other cases of low-grade B-cell lymphoproliferations reported after transplantation, is related to immunosuppression and therefore part of the spectrum of PTLDs, or merely represents coincidental event occurring in an immunocompromised patient.
    Mesh-Begriff(e) Antineoplastic Agents/therapeutic use ; Cladribine/therapeutic use ; Flow Cytometry ; Heart Transplantation/adverse effects ; Humans ; Leukemia, B-Cell/diagnosis ; Leukemia, B-Cell/drug therapy ; Leukemia, B-Cell/pathology ; Leukemia, Hairy Cell/diagnosis ; Leukemia, Hairy Cell/drug therapy ; Leukemia, Hairy Cell/pathology ; Male ; Middle Aged ; Myocardial Ischemia/therapy ; Remission Induction ; Sensitivity and Specificity
    Chemische Substanzen Antineoplastic Agents ; Cladribine (47M74X9YT5)
    Sprache Englisch
    Erscheinungsdatum 2005-11-22
    Erscheinungsland United States
    Dokumenttyp Case Reports ; Journal Article
    ZDB-ID 1042374-6
    ISSN 1029-2403 ; 1042-8194
    ISSN (online) 1029-2403
    ISSN 1042-8194
    DOI 10.1080/10428190500254505
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 2997: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  2. Artikel ; Online: Feasibility of aspirin and/or vitamin D3 for men with prostate cancer on active surveillance with Prolaris® testing.

    Dinneen, Eoin / Shaw, Gregory L / Kealy, Roseann / Alexandris, Panos / Finnegan, Kier / Chu, Kimberley / Haidar, Nadia / Santos-Vidal, Sara / Kudahetti, Sakunthala / Moore, Caroline M / Grey, Alistair D R / Berney, Daniel M / Sahdev, Anju / Cathcart, Paul J / Oliver, R Timothy D / Rajan, Prabhakar / Cuzick, Jack / Madaan, Sanjeev / Pati, Jhumur /
    Chowdhury, Abdul M / Birch, Brian R P / Dudderidge, Timothy J / Jefferson, Kieran P / Kynaston, Howard G / Green, James S A / Powles, Thomas / Kemp, Victoria / Chu, Kimberly

    BJUI compass

    2022  Band 3, Heft 6, Seite(n) 458–465

    Abstract: Objectives: To test the feasibility of a randomised controlled trial (RCT) of aspirin and/or vitamin D3 in active surveillance (AS) low/favourable intermediate risk prostate cancer (PCa) patients with Prolaris® testing.: Patients and methods: Newly- ... ...

    Abstract Objectives: To test the feasibility of a randomised controlled trial (RCT) of aspirin and/or vitamin D3 in active surveillance (AS) low/favourable intermediate risk prostate cancer (PCa) patients with Prolaris® testing.
    Patients and methods: Newly-diagnosed low/favourable intermediate risk PCa patients (PSA ≤ 15 ng/ml, International Society of Urological Pathology (ISUP) Grade Group ≤2, maximum biopsy core length <10 mm, clinical stage ≤cT2c) were recruited into a multi-centre randomised, double-blind, placebo-controlled study (ISRCTN91422391, NCT03103152). Participants were randomised to oral low dose (100 mg), standard dose (300 mg) aspirin or placebo and/or vitamin D3 (4000 IU) versus placebo in a 3 × 2 factorial RCT design with biopsy tissue Prolaris® testing. The primary endpoint was trial acceptance/entry rates. Secondary endpoints included feasibility of Prolaris® testing, 12-month disease re-assessment (imaging/biochemical/histological), and 12-month treatment adherence/safety. Disease progression was defined as any of the following (i) 50% increase in baseline PSA, (ii) new Prostate Imaging-Reporting and Data System (PI-RADS) 4/5 lesion(s) on multi-parametric MRI where no previous lesion, (iii) 33% volume increase in lesion size, or radiological upstaging to ≥T3, (iv) ISUP Grade Group upgrade or (v) 50% increase in maximum cancer core length.
    Results: Of 130 eligible patients, 104 (80%) accepted recruitment from seven sites over 12 months, of which 94 patients represented the per protocol population receiving treatment. Prolaris® testing was performed on 76/94 (81%) diagnostic biopsies. Twelve-month disease progression rate was 43.3%. Assessable 12-month treatment adherence in non-progressing patients to aspirin and vitamin D across all treatment arms was 91%. Two drug-attributable serious adverse events in 1 patient allocated to aspirin were identified. The study was not designed to determine differences between treatment arms.
    Conclusion: Recruitment of AS PCa patients into a multi-centre multi-arm placebo-controlled RCT of minimally-toxic adjunctive oral drug treatments with molecular biomarker profiling is acceptable and safe. A larger phase III study is needed to determine optimal agents, intervention efficacy, and outcome-associated biomarkers.
    Sprache Englisch
    Erscheinungsdatum 2022-06-11
    Erscheinungsland United States
    Dokumenttyp Journal Article
    ISSN 2688-4526
    ISSN (online) 2688-4526
    DOI 10.1002/bco2.169
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

    Fernleihe an ZB MED

    Sie können sich den gewünschten Titel als lokale Nutzerin oder lokaler Nutzer von ZB MED direkt an den Standort Köln schicken lassen.

  3. Artikel: The relationship of nodular endocardial infiltrates (Quilty lesions) to survival, patient age, anti-HLA antibodies, and coronary artery disease following heart transplantation.

    Chu, Kimberly E / Ho, Eric K / de la Torre, Ludwika / Vasilescu, Elena R / Marboe, Charles C

    Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology

    2005  Band 14, Heft 4, Seite(n) 219–224

    Abstract: Background: Quilty lesions are mononuclear cell infiltrates identified in human heart transplant biopsies. The biologic significance of Quilty lesions remains undetermined.: Methods: We monitored acute rejection by biopsy and lymphocyte growth assay ( ...

    Abstract Background: Quilty lesions are mononuclear cell infiltrates identified in human heart transplant biopsies. The biologic significance of Quilty lesions remains undetermined.
    Methods: We monitored acute rejection by biopsy and lymphocyte growth assay (LGA) as well as transplant-related coronary artery disease (TRCAD) by yearly angiogram in 285 recipients of primary heart allografts. Patients showing Quilty lesions on biopsies during the first year posttransplant were compared with patients without such lesions. Recipients' sera were obtained at the time of biopsy and tested for anti-HLA Class I and II antibodies.
    Results: The actuarial survival of patients who developed Quilty lesions was significantly better than those who did not (P=.0074). Patients with Quilty lesions were younger and more likely to have a biopsy diagnosis of acute rejection (P=.002) and positive LGA (P<.0001) during the first posttransplant year. Among patients who do not form anti-HLA Class II antibodies, those with Quilty lesions were more likely than patients without Quilty lesions to develop TRCAD 5 years posttransplantation (P=.04). There was no correlation of Quilty status with the number of HLA donor-recipient mismatches or posttransplant development of anti-HLA antibodies.
    Conclusions: Quilty formers showed improved survival and are more likely to be diagnosed with acute rejection on biopsy and have positive LGAs. Allograft recipients who do not form anti-HLA Class II antibodies but do form Quilty lesions are more likely to develop TRCAD by 5 years posttransplantation than those who do not form Quilty lesions.
    Mesh-Begriff(e) Adolescent ; Adult ; Age Factors ; Antibodies/blood ; Biopsy ; Coronary Angiography ; Coronary Artery Disease/diagnosis ; Coronary Artery Disease/etiology ; Endocardium/immunology ; Endocardium/pathology ; Female ; Follow-Up Studies ; Graft Rejection/blood ; Graft Rejection/immunology ; Graft Rejection/pathology ; Heart Transplantation/immunology ; Histocompatibility Antigens Class I/immunology ; Histocompatibility Antigens Class II/immunology ; Humans ; Male ; Middle Aged ; Postoperative Complications ; Risk Factors ; Survival Analysis ; Time Factors
    Chemische Substanzen Antibodies ; Histocompatibility Antigens Class I ; Histocompatibility Antigens Class II
    Sprache Englisch
    Erscheinungsdatum 2005-07
    Erscheinungsland United States
    Dokumenttyp Comparative Study ; Journal Article
    ZDB-ID 1134600-0
    ISSN 1054-8807
    ISSN 1054-8807
    DOI 10.1016/j.carpath.2005.03.009
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 3572: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

Zum Seitenanfang